Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Condition Directory

Chronic Lymphocytic Leukemia clinical trials

Directory of U.S. ClinicalTrials.gov public records for Chronic Lymphocytic Leukemia. Browse Chronic Lymphocytic Leukemia recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 23, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1858
Shown on this page
12
Current sort
Recently updated
Condition scope
Chronic Lymphocytic Leukemia
Additional filters apply within this condition.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

How Chronic Lymphocytic Leukemia studies are organized in the registry

CLL is registered together with small lymphocytic lymphoma (SLL) in many records — they are treated as one disease in study design — so listings often carry both names. Drug-class abbreviations, particularly BTK and BCL-2 inhibitor terms, appear directly in current titles.

Terms that often appear in related listings
SLL BTK inhibitor relapsed CLL venetoclax

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Filter and sort this condition

These controls apply only within Chronic Lymphocytic Leukemia. Default order is Recently updated. Add location, sponsor, treatment, or recruitment status to narrow this condition page further.

Reset condition filters
Clear filters
Showing 277–288 of 1,858 matching trials for Chronic Lymphocytic Leukemia.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Recruiting No phase listed Observational

The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen

NCT01890486
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma, Germ Cell Neoplasms, Myelodysplastic Syndromes, Chronic Lymphocytic Leukemia, Immunodeficiency Diseases
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 23, 2026, 9:22 AM EDT
Recruiting Phase 2 Interventional

Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial

NCT05183854
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Pneumococcal 20-valent Conjugate Vaccine, Pneumococcal Polyvalent Vaccine
Biological
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 23, 2026, 9:22 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients

NCT05876923
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent Non-hodgkin Lymphoma
Interventions
Biospecimen Collection, Cardiopulmonary Exercise Testing, Dual X-ray Absorptiometry, Electronic Health Record Review, Exercise Intervention, Physical Examination, Questionnaire Administration, Spirometry, Physical Performance Testing, Best Practice
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 23, 2026, 9:22 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

NCT06428019
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Venetoclax, Acalabrutinib, Obinutuzumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
32
States / cities
Tucson, Arizona • Clovis, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 23, 2026, 9:22 AM EDT
Completed Phase 1 Interventional

Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

NCT04488354
View directory record Official record
Conditions
Relapsed/Refractory B-cell Lymphomas, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Chronic Lymphocytic Leukemia (CLL), Marginal Zone Lymphoma (MZL), Mantle Cell Lymphoma (MCL), Small Lymphocytic Lymphoma (SLL), Primary Mediastinal Large B Cell Lymphoma, Transformed Follicular Lymphoma, Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma, Burkitt Lymphoma
Interventions
CLBR001 and SWI019
Combination Product
Lead sponsor
Calibr, a division of Scripps Research
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
8
States / cities
Duarte, California • San Diego, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 23, 2026, 9:22 AM EDT
Active, not recruiting Phase 1 Interventional

A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies

NCT03085173
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL), Relapsed, Refractory
Interventions
EGFRt/19-28z/4-1BBL CAR T cells
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 23, 2026, 9:22 AM EDT
Completed Not applicable Interventional

Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study

NCT05972577
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aplastic Anemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Plasma Cell Myeloma
Interventions
Health Promotion and Education, Medical Device Usage and Evaluation, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
60 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 23, 2026, 9:22 AM EDT
Completed Phase 2 Interventional

Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT02518555
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Ibrutinib, Laboratory Biomarker Analysis, Pharmacological Study, Pneumococcal 13-valent Conjugate Vaccine, Quality-of-Life Assessment, Trivalent Influenza Vaccine
Biological · Drug · Other
Lead sponsor
Jennifer Woyach
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 23, 2026, 9:22 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL

NCT03467867
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Venetoclax, Rituximab, Rituximab/Hyaluronidase Human
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 23, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide

NCT01723839
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL)
Interventions
Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 23, 2026, 9:22 AM EDT
Recruiting No phase listed Observational

Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma

NCT07030400
View directory record Official record
Conditions
Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL)
Interventions
Bruton's tyrosine kinase inhibitor, B-Cell Lymphoma 2 Protein Inhibitor
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 23, 2026, 9:22 AM EDT
Recruiting Not applicable Interventional

Survivors Uniting for Remote Guided Exercise

NCT07290309
View directory record Official record
Conditions
Cancer, Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma), Physical Activity, Physical Activity Behavior, Cancer (With or Without Metastasis), Cancer - Chronic Lymphocytic Leukemia, Cancer - Ovarian
Interventions
Virtually Supervised Exercise Sessions, Asynchronous Group
Behavioral
Lead sponsor
Colorado State University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 23, 2026, 9:22 AM EDT

About this Chronic Lymphocytic Leukemia clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Chronic Lymphocytic Leukemia as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Chronic Lymphocytic Leukemia.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Chronic Lymphocytic Leukemia.